GlassScriptPhysician profile
Seth M Guidry
NPI 1144607151
$2,132.04
in general payments reported to CMS, 2019-2025
19 companies · $876 in 2025
The $876 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $557 · 2024: $574 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,943 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,942.90 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $755.08 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $309.44 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Neurocrine Biosciences, INC. | $193.38 | 2022-2025 | Ingrezza, Ongentys |
| Axsome Therapeutics, INC. | $116.37 | 2025 | Auvelity |
| Pfizer INC. | $114.04 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.38 | 2025 | Caplyta |
| Lilly USA, LLC | $93.33 | 2022-2025 | Mounjaro, Reyvow, Emgality |
| Abbvie INC. | $75.20 | 2023-2025 | |
| Lundbeck LLC | $55.99 | 2024-2025 | Vyepti |
| Neurelis, INC. | $55.29 | 2024-2025 | Valtoco |
| Janssen Biotech, INC. | $52.89 | 2025 | |
| Exact Sciences Corporation | $46.70 | 2025 | The Cologuard Plus Collection Kit |
| Ucb, INC. | $45.66 | 2024-2025 | Briviact |
| Antares Pharma, INC. | $22.79 | 2024 | Xyosted |
| Seqirus USA INC | $22.79 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $22.40 | 2023 | Vercise |
| Takeda Pharmaceuticals U.S.A., INC. | $17.08 | 2025 | Hyqvia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.17 | 2024 | Xifaxan |
| Currax Pharmaceuticals LLC | $14.06 | 2025 | Contrave, Onzetra Xsail |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Guidry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.